Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

Share-based compensation

9 Months Ended

Sep. 30, 2024

Note 11 — Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended			Nine months ended
		September 30,			September 30,
	2024		2023		2024		2023
Research and development	$	1,069	$	789	$	2,878	$	2,190
Selling, general and administrative		1,985		2,394		6,337		6,506
	$	3,054	$	3,183	$	9,215	$	8,696

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended			Nine months ended
		September 30,			September 30,
	2024		2023		2024		2023
Number of options over ordinary shares granted		10,856,580		7,082,892		54,839,004		59,070,294
Weighted average fair value of ordinary shares options	$	0.13	$	0.12	$	0.12	$	0.12
Number of additional options with a nominal exercise price granted		3,001,032		465,960		33,656,856		26,480,652
Weighted average fair value of options with a nominal exercise price	$	0.16	$	0.15	$	0.15	$	0.27